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Summary Type 2 diabetes (T2DM) is associated both with cognitive decrements and depressive
symptoms. Since depression in itself has been associated with cognitive decrements we aimed to
investigate the influence of depressive symptoms on the relation between T2DM and cognitive
functioning.
Data were derived from three independent studies on cognitive functioning in patients with
T2DM (n = 366) and controls without diabetes (n = 204), two with longitudinal and one with only
cross-sectional assessments. Depressive symptoms were measured with self-report inventories
(CES-D or BDI-II). The composite z-score of the domains memory, information-processing speed,
and attention and executive function was the primary cognitive outcome measure. Mixed linear
regression analyses were used in a stepped approach to compare cognitive functioning between
(1) patients with T2DM and controls (cross-sectionally and longitudinally), (2) participants with
and without depressive symptoms, separately for patients and controls, and (3) patients and
controls after adjustment for depressive symptoms. In addition the mediating effect of depres-
sive symptoms was assessed with a bootstrapping technique.
Depressive symptoms were present in 11% of the patients with T2DM and in 7% of controls
( p = 0.15). Cognitive performance in patients with T2DM was worse than in controls (overall
difference composite z-score 0.13). However, T2DM was not associated with accelerated
cognitive decline over three years of follow-up relative to controls. Controls with depressive
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symptoms performed worse than those without depressive symptoms, although not statistically
significant. Performance in patients with T2DM with and without depressive symptoms was similar.
Adjustment for depressive symptoms and estimation of the mediating effect showed that the
difference between patients and controls was not mediated by depressive symptoms.
In conclusion, the modest cognitive decrements that are associated with T2DM are not due to the
presence of mild depressive symptoms.
# 2012 Elsevier Ltd. 
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In patients with type 2 diabetes (T2DM) small decrements in
cognitive functioning are consistently found on the domains
memory, information-processing speed, and attention and
executive functioning (Awad et al., 2004). Diabetes is also an
established risk factor for dementia, with an up to twofold
increased risk (Ott et al., 1999; Biessels et al., 2006). In
addition, depressive symptoms are more common among
patients with T2DM (Anderson et al., 2001; Ali et al.,
2006; Mezuk et al., 2008; Pan et al., 2010) with depression
occurring twice as often in patients with diabetes compared
to individuals without diabetes (Anderson et al., 2001).
In the general population, depressive symptoms are asso-
ciated with lower cognitive performance and an increased
risk for dementia (Jorm, 2000; Ownby et al., 2006). In people
with depressive symptoms impairments are found in the
domains memory and information-processing speed (Alexo-
poulos et al., 2002; Butters et al., 2004; Airaksinen et al.,
2007). Therefore, the question arises whether depressive
symptoms play a mediating role in the relation between
T2DM and cognitive functioning and cognitive decline. In a
meta-analysis of three studies, all with the same detailed
standardized neuropsychological assessment, we studied the
influence of depressive symptoms on the relation between
T2DM and cognitive functioning in a cross-sectional and long-
itudinal design.
2. Methods
Data were derived from three studies that assessed cognitive
functioning in patients with T2DM relative to controls: the
ADDITION-Netherlands study (Koekkoek et al., 2012), the
UDES (van den Berg et al., 2010) and the Hoorn study (van
den Berg et al., 2008).
2.1. Design of the studies
The ADDITION study (Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes in Pri-
mary Care) was a cluster-randomised trial in patients with
screen-detected T2DM that compared the effectiveness of an
intensive multifactorial treatment with routine care on car-
diovascular outcome (Griffin et al., 2011). The study started
with a population-based screening for diabetes followed by
inclusion of newly diagnosed patients with diabetes in the
trial. In a subgroup of patients from The Netherlands cogni-
tion was assessed through two standardized neuropsycholo-
gical assessments, in 2006—2007 and again in 2009—2010
(Koekkoek et al., 2012). Control participants without dia-
betes were recruited among spouses and acquaintances of
the patients.The UDES (Utrecht Diabetic Encephalopathy Study) was a
longitudinal study on determinants of impaired cognition in
patients with T2DM in The Netherlands (van den Berg et al.,
2010). Patients were recruited through their general practi-
tioner. Controls were recruited among spouses and acquain-
tances of the patients. They were first examined between
2002 and 2004 and again four years later (2006—2009).
The Hoorn study was a population-based cohort study on
glucose metabolism, which started in 1989 in the middle-
sized town of Hoorn, The Netherlands (Mooy et al., 1995). A
random sample of inhabitants of Hoorn was invited to parti-
cipate in the study. Over the years three follow-up examina-
tions were performed (Mooy et al., 1995; de Vegt et al., 2001;
van den Berg et al., 2008). In the third follow-up examination
cognitive functioning was assessed (van den Berg et al.,
2008). For the present study participants of the Hoorn study
were reclassified based on their fasting glucose of the last
follow-up examination in patients with T2DM and control
subjects.
The ADDITION study and the UDES were approved by the
medical ethics committee of the University Medical Center
Utrecht, The Netherlands. The Hoorn study was approved by
the medical ethics committee of the VU University Medical
Center, Amsterdam, The Netherlands. Written informed con-
sent was obtained from all participants.
2.2. Study populations
Fig. 1 represents a flowchart demonstrating drop-out and
follow-up of the three studies. The first neuropsychological
assessment in the ADDITION study was performed in 183
patients with screen-detected T2DM, aged between 50 and
70 years. Their diabetes was screen-detected approximately
three years before, following a standardized protocol (Jans-
sen et al., 2007). Classification was done according to the
WHO-criteria (WHO, 1999). Of these patients 135 were re-
examined three years later. During the second examination
eight patients did not complete a depressive symptoms
questionnaire and were therefore excluded for the long-
itudinal analyses. In the UDES 122 patients aged between
56 and 80 years, known with T2DM for at least one year,
underwent the first neuropsychological assessment. Twenty-
three patients were excluded from the present analyses as
sixteen patients had no baseline depressive symptoms ques-
tionnaire and seven had no estimated level of (crystallized)
intelligence. Four years later 68 patients completed the
second neuropsychological assessment. Participants of the
Hoorn study were aged 50—75 years at recruitment. For a
diagnosis of diabetes fasting blood glucose was measured and
subsequently an oral glucose tolerant test (OGTT) was admi-
nistered and classified according to the WHO-criteria (WHO,
1999). Participants already known with diabetes and/or
using glucose-lowering therapy were categorized as having
Figure 1 Flowchart of study participants. T2DM: type 2 diabetes; con: controls.
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at the third examination and received a neuropsychological
assessment. One person with a missing baseline depressive
symptoms questionnaire and one without estimated level of
(crystallized) intelligence measured were excluded.
Sixteen control participants of the UDES were also used
as controls in the ADDITION-study. For the present pooled
analyses these sixteen controls were only included in the
population of the UDES. From all three studies only con-
trol participants with a fasting glucose 5.6 mmol/L were
included. This left 39, 33 and 132 controls from the
ADDITION, UDES and Hoorn study respectively for inclu-
sion in the present pooled analysis.
All participants were functionally independent and Dutch
speaking. None of them had a history of neurological or
psychiatric disorders that could influence cognitive function-
ing or a history of alcohol or substance abuse. Individuals with
a previous non-disabling stroke (i.e. without interference
with usual daily activities) could participate.
2.3. Neuropsychological assessment
The neuropsychological assessments in all three studies
included the same nine tests addressing three cognitive
domains, that are most consistently affected in T2DM in
previous studies (Awad et al., 2004): memory, information-
processing speed, and attention and executive functioning.
The division in cognitive domains was made a priori, accord-
ing to neuropsychological practice and cognitive theory
(Lezak et al., 2004). The domain ‘memory’ was subdivided
in four domains: working memory, immediate memory and
learning rate, forgetting rate, and incidental memory. Work-
ing memory was assessed by the forward and backward digitspan of the Wechsler Adult Intelligence Scale — 3rd edition
(WAIS-III) (Wechsler, 1997) and the Corsi Block-tapping Task
(Kessels et al., 2000). The product scores of both measures
(number correct times span length) were used. Immediate
memory and learning rate was assessed with the Rey Auditory
Verbal Learning Test (RAVLT) (Van der Elst et al., 2005) and
the Location Learning Test (LLT) (Bucks et al., 2000). For the
RAVLT the mean of the total number of words remembered in
five learning trials was recorded and a learning index was
calculated. For the LLT the total number of displacements
over five trials and a learning index was calculated. Forget-
ting rate was calculated in the RAVLT and the LLT by correct-
ing the scores in the delayed recall condition for the score
obtained in the fifth learning trial. Incidental memory was
measured with the delayed recall of the Rey-Osterrieth
Complex Figure Test (Rey, 1941). This score was also cor-
rected for the score obtained in the copy condition. The
domain ‘information-processing speed’ was assessed by the
Trail-making Test Part A (TMT-A) (Corrigan and Hinkeldey,
1987), the Stroop Color-Word Test (part 1 and 2) (Stroop,
1935) and the subtest Symbol Digit Substitution of the WAIS-III
(SS-WAIS-III). Time to complete the TMT-A task was recorded
in seconds; the mean of the total time needed to complete
part I and II of the Stroop was calculated and for the SS-WAIS-
III the total correct numbers of copied symbols within two
minutes was recorded. The domain ‘attention and executive
functioning’ was assessed by the Trail-making Test Part B
(ratio score) (Corrigan and Hinkeldey, 1987), the Stroop
Color-Word Test (part 3; ratio score), the Brixton Spatial
Anticipation Test (Burgess and Shallice, 1997) recording
the number of errors, and a letter fluency test using
the letters ‘N’ and ‘A’ and a category fluency test (animal
naming) recording the total number of correct responses
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Adult Reading Test was used to estimate level of (crystal-
lized) intelligence (Schmand et al., 1992). The tests were
administered in a fixed order by neuropsychologists and
neuropsychologists in training and took about 90 min to
complete.
Raw test scores at first and second neuropsychological
assessment were standardized into z-scores per test, using
the pooled mean of baseline scores of all control participants
of the three studies. The z-scores of each domain were calcu-
lated by averaging the test scores comprising that domain. The
primary cognitive outcome measure was defined as the mean
composite z-score of the domains memory, information-pro-
cessing speed and attention and executive function.
In the ADDITION and Hoorn study depressive symptoms
were assessed with the validated Dutch version of the 20-
item Centre for Epidemiologic Studies Depression Scale (CES-
D) (Bouma et al., 1995) and in the UDES with the Dutch
version of the Beck Depression Inventory 2nd Edition (BDI-II)
(Beck et al., 1996). Both are self-report questionnaires to
measure the presence of depressive symptoms on a four-
point scale. Higher scores indicate more depressive symp-
toms. A score 16 on the CES-D and a score of >13 on the BDI
is generally accepted as the cut off score for the presence of
depressive symptoms (Radloff, 1977; Beekman et al., 1997).
The accuracy of these depressive screening instruments was
examined by Katz et al., who found comparable sensitivities
and specificities for the CES-D and the BDI when the cut off
scores were respectively 16 and >13 (Katz et al., 2004).Table 1 Patient characteristics per study of patients with T2DM
ADDITION UD
Type 2
diabetes
Controls Ty
dia
n 183 39 99
Age (yr) 63.0  5.4 62.3  6.5 65
Sex (% male) 61.2 28.2 * 51
Estimated level of
(crystallized) IQ
96.8  19.4 106.4  16.1 * 97
BMI (kg/m2) 30.6  4.8 26.2  3.6 * 28
Systolic blood pressure
(mmHg)
143.7  19.6 145.1  24.9 14
Diastolic blood pressure
(mmHg)
82.0  10.4 83.1  11.8 82
HbA1c (%) 6.2  0.5 5.4  0.2 * 6.9
Total cholesterol
(mmol/L)
4.1  1.0 5.7  0.8 * 5.0
Depressive symptoms
present (%)
9.8 10.3 9.5
CES-D/BDI-scorea 4 (1—8) 6 (2—11) 6 (
Diabetes duration (yr) 3.6  0.6 NA 8.6
Hypoglycemic
medication (%)
Metformin 48.6 61
Sulfonylurea 18.0 55
Thiazolidinediones 12.6 6.1
Insulin 0 29
* p-Value < 0.01 within a study between patients with T2DM and con
a Median with interquartile range. In the ADDITION and Hoorn-study Therefore these cut off scores were used to classify depres-
sive symptoms as absent or present.
2.4. Clinical characteristics
At the time of the neuropsychological assessments body
weight, height, waist circumference and blood pressure were
measured and body mass index (BMI) was calculated. Demo-
graphic variables and medical history were recorded in a
standardized interview. Venous blood samples were drawn
after an overnight fast to determine fasting blood glucose,
HbA1c and total cholesterol. The specific protocols are
described in the separate studies (van den Berg et al.,
2008, 2010; Koekkoek et al., 2012).
2.5. Statistical analyses
Categorical variables are reported as numbers and percen-
tages, continuous variables as means with standard devia-
tions (SD) and not normally distributed variables as median
with interquartile range (IQR). Within the studies, differ-
ences between the patients with diabetes and control sub-
jects were analyzed with Chi-square tests for categorical
variables, independent t-tests for normally distributed con-
tinuous variables and Mann—Whitney tests for not normally
distributed continuous variables.
Mean cognitive domain scores were calculated by averaging
the test scores comprising that domain and comparisons and controls.
ES Hoorn
pe 2
betes
Controls Type 2
diabetes
Controls
 33 84 132
.6  5.8 64.3  6.0 74.5  6.0 73.6  6.1
.2 42.1 51.2 42.4
.7  14.3 101.9  14.0 96.4  13.2 100.8  12.8
.4  4.3 25.8  3.6 28.1  4.2 26.1  3.4 *
7.7  19.8 139.0  19.5 151.9  22.4 145.5  21.6
.6  10.8 80.0  9.4 75.4  11.8 73.8  11.9
  1.2 5.5  0.4 * 6.4  0.8 5.5  0.3 *
  0.9 5.8  1.1 * 4.8  1.0 5.4  1.1 *
 0 12.9 7.6
3—10) 3 (1—7) * 6 (2—10) 4 (1—8)
  6.1 NA 6.2  2.6 NA
.6 29.8
.6 22.6
 9.5
.3 4.8
trol subjects.
the CES-D was used; in the UDES the BDI.
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analyses adjusted for age, gender and estimated level of
(crystallized) intelligence. First, cognitive performance and
depressive symptoms were compared between the diabetic
and the control groups. Next, cognitive performance was
compared between participants with and without depressive
symptoms, separately for the diabetic and the control groups.
Finally, to examine whether the relation between cognitive
performance and diabetes status was mediated by depressive
symptoms, we added the presence of depressive symptoms as
a covariate in the first comparison. In addition, we estimated
the possible mediating effect of depression and corresponding
99%-confidence interval (CI) with a bootstrapping technique
(Preacher and Hayes, 2008). During bootstrapping the data set
is sampled repeatedly to estimate the mediating effect in each
resampled data set and reconstruct a 99%-CI. When the CI does
not contain zero a mediating effect is present. We computed
bootstrapped confidence intervals (5000 samples) for the size
of the specific mediating effects using SPSS macros provided by
Preacher and Hayes (2008).Figure 2 Cognitive scores in T2DM versus cIn the longitudinal analyses, mean change in cognition per
year was compared between the groups with and without
diabetes using mixed linear models adjusted for age, gender,
estimated level of (crystallized) intelligence. Because these
analyses did not show accelerated cognitive decline in
the group with diabetes, no further analyses on the possible
modulating effects of depression were performed.
Secondary analyses were performed for each of the cog-
nitive domains. In addition, to examine the influence of
cardiovascular disease, two post hoc analyses were per-
formed. In the first analyses participants with a history of
stroke were excluded. The second additionally adjusted the
primary comparisons for hypertension (defined by the use of
antihypertensive medication or a blood pressure above
160 mmHg systolic and/or 95 mmHg diastolic) and hyperch-
olesterolemia (defined by the use of cholesterol lowering
medication or total cholesterol above 6.5 mmol/L). The
analyses were performed per study and then combined in
a fixed-effect model (Review Manager 5, Cochrane Collabora-
tion). The I-squared (I2) statistic was calculated to quantifyontrols adjusted for age, gender and IQ.
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erogeneity (Higgins and Thompson, 2002). In case of an I2
above 50% a random-effect model was used. To minimize the
possibility of type 1 errors, a p-value of less than 0.01 was
considered statistically significant; therefore results are
reported with a 99%-confidence interval.
3. Results
Table 1 shows the characteristics for the control group and
patients with T2DM per study at the first neuropsychological
assessment. Participants in the Hoorn study were older and
T2DM patients in the UDES had a longer history of diabetes.
Depressive symptoms were present in 10—13% of the patients
with T2DM compared to 0—10% of the control participants
(Table 1). Overall, depressive symptoms were present in 11%
of the patients with T2DM and in 7% of controls ( p = 0.15).
3.1. Cognitive performance
In all three studies, patients with T2DM showed worse
cognitive performance than control participants with an
overall difference in composite z-score of 0.13 (99%-CI
0.22 to 0.04; p < 0.001) (Fig. 2). Secondary analyses forFigure 3 Cognitive scores in controls: depressive symptoms versthe separate cognitive domains showed overall differences
of 0.08 (memory), 0.14 (attention and executive func-
tion) and 0.18 (information-processing speed).
Because the UDES had no control participants with depres-
sive symptoms, this study could not be included in the meta-
analysis for the comparison of controls with and without
depressive symptoms. In the other two studies the controls
with depressive symptoms performed worse than those with-
out depressive symptoms, although not significantly (overall
difference composite z-score 0.25; 99%-CI 0.54 to 0.03;
p = 0.02) (Fig. 3). Secondary analyses for the separate
domains showed similar results. Also, no difference was
found between patients with T2DM with and without depres-
sive symptoms in any of the three studies on any of the
domains (overall difference composite z-score 0.01; 99%-CI
0.15 to 0.18; p = 0.82) (Fig. 4).
Adjustment for depressive symptoms did not influence the
difference in cognitive performance between patients with
diabetes and controls; the difference in overall composite
score remained 0.13 (99%-CI 0.23 to 0.03; p < 0.001)
(Fig. 5). These results were confirmed by bootstrapping
the mediating effect, with a mediating effect of depressive
symptoms below 0.01 for all cognitive domains in all three
studies (results not shown).us no depressive symptoms, adjusted for age, gender and IQ.
Figure 4 Cognitive scores in T2DM: depressive symptoms versus no depressive symptoms, adjusted for age, gender and IQ.
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history of stroke, another adjusting for hypertension and
hypercholesterolemia, did not change the results (results
not shown).
3.2. Cognitive decline
Cognitive decline was assessed in a pooled analysis of the
ADDITION study and the UDES. Over a period of three to four
years patients with T2DM showed no greater decline than
control participants (overall difference in decline per year on
composite score 0.01; 99%-CI 0.04 to 0.02; p = 0.21)
(Fig. 6). We did not perform further longitudinal analyses
on the mediating effect of depressive symptoms as no accel-
erated decline was found.
4. Discussion
The present study demonstrated more cognitive decrements
in diabetes patients compared to controls. Controls with
depressive symptoms performed worse than those without
depressive symptoms, although not statistically significant,but performance in diabetes patients with and without
depressive symptoms was similar. The pooled analysis,
including over 350 patients and 200 controls, showed that
cognitive decrements in patients with T2DM are not influ-
enced by the presence of depressive symptoms.
Previous studies reported similar prevalence rates of co-
morbid depressive symptoms in patients with T2DM com-
pared to our sample. In a review examining the prevalence
of co-morbid depression in diabetes, measured by self-report
questionnaires, prevalence rates ranged from 8 to 31% in
patients with T2DM with an overall prevalence of 18% (Ali
et al., 2006) and between 5 and 24% in people without
diabetes, with an average of 10%. A study in The Netherlands
that administered the CES-D to a community-based sample of
older adults, aged 55—85 years, found an overall prevalence
of depressive symptoms (CES-D  16) of 17% in patients with
T2DM (Pouwer et al., 2003). In the three included studies, the
prevalence rates of depressive symptoms were in the low
range of other studies and were not significantly different
between diabetes patients and controls, which might have
been influenced by selection bias. People with a depressive
disorder often do not participate in research. Besides, they
are often excluded from the analyses due to their depressive
Figure 5 Cognitive scores in T2DM versus controls adjusted for age, gender, IQ and depressive symptoms.
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ADDITION study and the UDES; people with a diagnosis of
severe depression were excluded.
Over the three studies, the difference in cognitive func-
tioning between patients with T2DM and controls was at the
lower end of the range of differences reported in other
studies (Awad et al., 2004; van den Berg et al., 2009).
Diabetes-associated decrements are often reported in other
studies with effect sizes up to 0.6 (Awad et al., 2004; van den
Berg et al., 2009). In accordance with the literature the
domains information-processing speed and attention and
executive functioning are most affected in the pooled ana-
lyses. In contrast, the domain memory showed no significant
difference between patients and controls in our study (Awad
et al., 2004; van den Berg et al., 2009; Reijmer et al., 2010).
Several factors may have attenuated the differences in
effect sizes. First of all, in our three cohorts patients with
diabetes were well controlled for their diabetes and for
vascular risk factors relative to control participants. Controls
were not excluded if they had elevated vascular risk factor
levels, therefore the contrast between participants with andwithout diabetes may be attenuated, as also hypertension
and elevated lipid levels play a role in cognition (van den Berg
et al., 2009). Another explanation might be that patients
with modest cognitive decrements were reluctant to parti-
cipate in research.
Both longitudinal studies found no difference in rate of
cognitive decline between diabetes patients and controls
which is in agreement with recent publication of a large study
(Euser et al., 2010). In this study participants were followed for
three years and no accelerated decline was found for both
those with diabetes and those with elevated fasting glucose or
insulin resistance (Euser et al., 2010). Other studies however
found an up to 1.5 to two times increased decline in cognition
compared to normal aging (Gregg et al., 2000; Fontbonne
et al., 2001; Yaffe et al., 2004).
Little research has been done on the effect of depressive
symptoms on cognitive functioning in patients with T2DM
(Awad et al., 2004). Most previous studies have adjusted their
analyses for the presence of depressive symptoms (Alexo-
poulos et al., 2002; Airaksinen et al., 2004; Butters et al.,
2004) and reported that the association between diabetes
Figure 6 Cognitive decline per year in patients with T2DM versus controls adjusted for age, gender and IQ.
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ment (Lowe et al., 1994; Gregg et al., 2000). One study
compared cognitive functioning between patients with T2DM
with and without a major depressive disorder (Watari et al.,
2006). Comparable to our study, they found no difference in
cognitive performance between the two groups. Probably,
diabetes-associated cognitive decrements and depressive
symptoms emerge independently from each other and have
different risk factors and etiologies.
In this article we included three studies that investigated
cognitive functioning in patients with T2DM through an
extensive neuropsychological assessment which was similar
in all studies. This gave us the opportunity to examine the
influence of depressive symptoms in a large group of patients
with diabetes. Participants with comorbid conditions asso-
ciated with type 2 diabetes (e.g. hypertension, dyslipidemia)
were included in the analyses to form a representative group
of diabetes patients. Nevertheless, our findings remained the
same after adjusting for these potential confounders. The
mean age of the participants over the three studies varied.
This might be a reason for the variation in prevalence rates of
depressive symptoms as elderly people more often have mild
depressive symptoms. To minimize the number of statistical
tests, we choose to divide the tests into cognitive domainsinstead of analyzing the effect of depressive symptoms per
test. We cannot exclude the possibility that a different
approach might have lead to different results. Furthermore,
it should be emphasized that cognitive functioning in the
study populations was within the range of normal aging and
that we only included people with mild depressive symptoms.
The results therefore might not be generalizable to people
with major depression or pathological cognitive decline.
In conclusion, the cognitive decrements in patients with
T2DM compared to people without diabetes are not influ-
enced by the mild depressive symptoms that are known to be
present in one out of six of these patients.
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